Ben B. Wolf, M.D., Ph.D.
For fun, Ben likes to race bicycles uphill – he has competed in many of the BUMPS (Bike Uphill Mountain Point Series) races.
As Chief Medical Officer and Head of Precision medicine, Ben Wolf leads the Company’s innovative clinical trials that transform therapeutic candidates into medicines with the potential to positively impact patient lives. Ben is a precision oncologist who brings to Relay Therapeutics nearly 20 years of experience in the biopharmaceutical industry, with expertise advancing new oncology programs in the clinic and optimizing patient selection to enable rapid proof of concept and registration. He has authored more than 40 peer-reviewed publications and has multiple patents related to drug discoveries.
Previously, Ben served as chief medical officer at KSQ Therapeutics, a biotechnology company advancing a pipeline of CRISPR-based tumor- and immune-focused drug candidates for the treatment of cancer. Prior to KSQ, he was senior vice president, clinical development at Blueprint Medicines, where he led efforts advancing multiple precision medicine programs for novel kinase inhibitors from investigational new drug (IND) applications to clinical proof-of-concept and registration (AyvakitTM; Gavretoâ). Prior to Blueprint, Ben held clinical and translational roles at Genentech, Amgen, Merrimack Pharmaceuticals and ImmunoGen.
Ben holds a B.S. from Union College and an M.D. and Ph.D. in biochemistry from the University of Virginia. He completed medical training in internal medicine and medical oncology at the University of California at San Diego.